Economic insights and deficits in European biotechnology patent policy
The decisive statutory provision of the EU for patent protection of genetic engineering inventions is the so-called directive on biotechnological patents (DBP). Its objective is the encouragement of research and development in the genetic engineering sector. The following exposition shows that the DBP has two major flaws from the economist's point of view, under which particularly small and medium-sized enterprises, the driving force of this young line of business, suffer.
(This abstract was borrowed from another version of this item.)
Volume (Year): 37 (2002)
Issue (Month): 3 (May)
|Contact details of provider:|| Web page: http://www.springerlink.com/link.asp?id=113472|
|Order Information:||Web: http://link.springer.de/orders.htm|
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Klemperer, Paul, 1990.
"How Broad Should the Scope of Patent Protection Be?,"
CEPR Discussion Papers
392, C.E.P.R. Discussion Papers.
- Paul Klemperer, 1990. "How Broad Should the Scope of Patent Protection Be?," RAND Journal of Economics, The RAND Corporation, vol. 21(1), pages 113-130, Spring.
- Denicolo, Vincenzo, 1999. "The optimal life of a patent when the timing of innovation is stochastic," International Journal of Industrial Organization, Elsevier, vol. 17(6), pages 827-846, August.
When requesting a correction, please mention this item's handle: RePEc:spr:intere:v:37:y:2002:i:3:p:150-155. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Guenther Eichhorn)or (Christopher F Baum)
If references are entirely missing, you can add them using this form.